Changes in High Sensitive C Reactive Protien With Different Treatment Modalities in Acute Pancreatitis

November 9, 2018 updated by: Mahmoud Abdelhamed, Assiut University
changes in high sensitive C reactive protien with different treatment modalities in acute pancreatitis

Study Overview

Status

Unknown

Conditions

Intervention / Treatment

Study Type

Observational

Enrollment (Anticipated)

80

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Egypt
      • Assuit, Egypt, 171516
        • Assiut University

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 75 years (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Sampling Method

Probability Sample

Study Population

Patients with acute pancreatitis

Description

Inclusion Criteria:

  • Age>=18 years

  • Diagnosis of acute pancreatitis confirmed by at least 2 of the following:

    1. Typical epigastric abdominal pain
    2. Elevation amylase/lipase >3 times upper limit normal and/or
    3. Confirmatory findings on cross-sectional imaging
    4. Enrollment within 8 hours of presentation

Exclusion Criteria:

  • Class II or greater NYHA heart failure
  • Oxygen dependent COPD
  • Chronic kidney disease>stage 2
  • Existing necrosis on abdominal CT
  • Organ dysfunction prior to enrollment
  • Sepsis
  • Acute respiratory distress syndrome
  • Malignancy not in remission for at least 5 years
  • Active drug use
  • Known allergy to dexamethasone
  • Altered mental status
  • Insulin-requiring diabetes
  • Abdominal surgery within 60days

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
Patients with acute pancreatitis
All patients will recive different lines of treatment {saline,antibiotics,dexamethasone}
Diagnostic test: High sesitive C reactive protien
High sesitive C reactive protien will be evaluated at admission time and after 36 hours

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
High sesitive C reactive protien
Time Frame: 72hours
Level of High sesitive C reactive protien expected to be changed with different lines of treatment and will be compaered
72hours
Serum Amylase
Time Frame: 72hours
Level of Serum Amylase expected to be changed with different lines of treatment and will be compaered
72hours
Serum Lipase
Time Frame: 72hours
Level of Serum Lipase expected to be changed with different lines of treatment and will be compaered
72hours

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Assiut University

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Anticipated)

November 9, 2018

Primary Completion (Anticipated)

November 9, 2018

Study Completion (Anticipated)

October 8, 2019

Study Registration Dates

First Submitted

October 11, 2018

First Submitted That Met QC Criteria

November 9, 2018

First Posted (Actual)

November 14, 2018

Study Record Updates

Last Update Posted (Actual)

November 14, 2018

Last Update Submitted That Met QC Criteria

November 9, 2018

Last Verified

November 1, 2018

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • CHCPWDTM

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Pancreatitis, Acute

Clinical Trials on High sesitive C reactive protien

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Congo

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe